
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences Inc's potential for stock growth is underpinned by its promising product candidate KSI-301, which aims to treat prevalent retinal diseases and has shown advancements in delivery methods, reducing dosing times significantly in ongoing Phase 3 trials. The company’s tarcocimab has exhibited strong durability, with encouraging results reported from pivotal trials such as GLOW1 and BEACON, indicating non-inferiority against standard treatments, and supporting future prospects in diabetic retinopathy and retinal vein occlusion. As the retinal disease therapy landscape evolves with competitive options, Kodiak's ability to demonstrate differentiated efficacy and safety in the upcoming GLOW2 and DAYBREAK trials will be crucial for solidifying its market position and enhancing investor confidence.
Bears say
Kodiak Sciences Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the unsuccessful Phase 3 trials of its product candidate, tarcocimab, which resulted in an unexpected increase in cataract adverse events. The company reported a substantial net loss of $43.9 million for the third quarter of 2024, raising concerns about its ability to secure sufficient capital resources to fund ongoing operations and program development. Additionally, the challenges associated with the previous tarcocimab formulation, including prolonged delivery time and potential adverse effects, further complicate the investment thesis by casting doubt on the commercial viability of its developmental candidates.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares